NA Proactive news snapshot: NEO Battery Materials, Organic Garage, Unigold, Braxia Scientific, Starton Therapeutics …
A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive
NEO Battery Materials Ltd (CVE:NBM) (OTCMKTS:NBMFF) recently announced that its s silicon (Si) nanocoating technology successfully achieved an ultra-fast charging/discharging capability in a half-cell coin test. Following a new test conducted by the laboratory of Dr Jong Hyeok Park, who is also Neo s chief scientific advisor, the company said the “breakthrough results” showed the potency of NEO s nanocoating technology through “superior charging/discharging performance on small battery cells.” Significantly, NEO s nanocoated silicon anode allows for “a safe full charge within 5 minutes,” which demonstrates potential for scaling and implementation in larger cells such as those used in high power E
The higher confidence measured and indicated (M&I) resource, at 1.682 million tonnes of lithium carbonate equivalent, has increased by 125% at the 800.
TRACON Pharmaceuticals presents Phase 1 study data of uliledlimab and atezolizumab at American Society of Clinical Oncology meeting
Data were presented from 20 refractory cancer patients with advanced or metastatic solid tumors treated with the combination of the drugs Uliledlimab was safe and well-tolerated as a monotherapy and in combination with atezolizumab
TRACON Pharmaceuticals Inc (NASDAQ:TCON) has presented updated data from its Phase 1 study of TJ004309 (uliledlimab) and Tecentriq (atezolizumab) at the American Society of Clinical Oncology (ASCO) virtual annual meeting.
In poster presentation 2511 entitled “The safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer” the company said data were presented from 20 refractory cancer patients with advanced or metastatic solid tumors treated with the combination